Latest filingSep 16, 2026Most recent Form 4
PHIO
Phio Pharmaceuticals Corp.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/16 to 09/16. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$4.00M3 buys
Total selling$00 sells
Net open-market+$4.00M3 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period3transactions
- P · Open-market buys · dominant3 · 100%
Activity by reported role
A joint filing can contribute to multiple roles5transactions
- Director · dominant2 · 40%
- Chief executive officer1 · 20%
- CHAIR1 · 20%
- PRES1 · 20%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (2)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeBitterman Robert JCommon Stock, $.0001 par value · Direct
431,421Aug 18, 2026
Plott Ronald ToddCommon Stock, $.0001 par value · Direct
15,000Aug 19, 2026
Bradford Patricia ACommon Stock, $.0001 par value · Direct
57,651Sep 15, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 16 → Sep 16
LessMore
Top insiders
By absolute net value across the selected period- PT+$17.1k
- BA+$12.4k
- BJ+$10.6k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
PHIO transaction history
Filters apply within this company and selected period by defaultLatest insider transactions
Form 4 filings from last month. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #221907 | PHIO | Bradford Patricia A | DIR | buy | 12.0k | $1.23M | P | 09/16 | 09/15 |
| #12621 | PHIO | Plott Ronald Todd | DIR | buy | 15.0k | $1.71M | P | 08/20 | 08/19 |
| #10936 | PHIO | Bitterman Robert J | CHAIRPRESCEO | buy | 10.0k | $1.06M | P | 08/19 | 08/18 |
Phio Pharmaceuticals Corp. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Phio Pharmaceuticals Corp.?
BRADFORD PATRICIA A, Plott Ronald Todd, Bitterman Robert J.
When was the latest reported open-market purchase?
Bradford Patricia A reported a buy on Sep 15, 2026 valued at $1.23M. Read the SEC filing.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
Net open-market buying in the selected period was $40,060.00. This describes filed transactions, not a bullish rating.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.